An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the response of several biomarkers in patients treated
with ARQ 501. The results of the study may help the sponsor understand the effect of the
study drug on these biomarkers and their respective role in cancer growth control.
Phase:
Phase 1
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)